Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00044733 | Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant | PHASE2 | COMPLETED | 38 | — | — | Mar 1, 2000 | Sep 1, 2004 | May 18, 2006 | 13 | United States |
| Name | Type | Description |
|---|---|---|
| Mylotarg (gemtuzumab ozogamicin) Injection | DRUG | - |
Inclusion Criteria * Patients with CD33+ AML who have experienced relapse after autologous or allogeneic HSCT. Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33 positive, based on local laboratory criteria (Patients with history of MDS pretransplant...